1.            Elsana, H. et al. A short peptide protects from age-onset proteotoxicity. Aging Cell 22, (2023).

2.            Hemed-Shaked, M. et al. MTADV 5-MER peptide suppresses chronic inflammations as well as autoimmune pathologies and unveils a new potential target-Serum Amyloid A. J. Autoimmun. 124, (2021).

3.            Murai, T., Kawashima, H. & Naor, D. Editorial: Cell-Cell and Cell-Matrix Adhesion in Immunobiology and Cancer. Front. Immunol. 10, (2020).

4.            Beider, K. et al. Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease. Oncotarget 8, 90748–90765 (2017).

5.            Pinner, E. et al. CD44 Splice Variants as Potential Players in Alzheimer’s Disease Pathology. J. Alzheimer’s Dis. 58, 1137–1149 (2017).

6.            Barzilay, R. et al. CD44 Deficiency Is Associated with Increased Susceptibility to Stress-Induced Anxiety-like Behavior in Mice. J. Mol. Neurosci. 60, 548–558 (2016).

7.            Naor, D. Editorial: Interaction between hyaluronic acid and its receptors (CD44, RHAMM) regulates the activity of inflammation and cancer. Front. Immunol. 7, (2016).

8.            Assayag-Asherie, N. et al. Can CD44 be a mediator of cell destruction? the challenge of type 1 diabetes. PLoS One 10, (2015).

9.            Gesundheit, B. et al. Therapeutic properties of mesenchymal stem cells for autism spectrum disorders. Med. Hypotheses 84, 169–177 (2015).

10.          Girbl, T. et al. CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility. Cancer Res. 73, 561–570 (2013).

11.          Shimony, O. et al. Anti-T lymphocyte globulin (ATG) induces generation of regulatory T cells, at least part of them express activated CD44. J. Clin. Immunol. 32, 173–188 (2012).

12.          Turley, E. A. & Naor, D. RHAMM and CD44 peptides-analytic tools and potential drugs. Front. Biosci. 17, 1775–1794 (2012).

13.          Kahaly, G. J. et al. Regulatory T-cells in Graves’ orbitopathy: Baseline findings and immunomodulation by anti-T lymphocyte globulin. J. Clin. Endocrinol. Metab. 96, 422–429 (2011).

14.          Naor, D., Wallach-Dayan, S. B., Zahalka, M. A. & Sionov, R. V. Involvement of CD44, a Molecule with a Thousand Faces, in Cancer Dissemination. in Hyaluronan in Cancer Biology 127–146 (Elsevier Inc., 2009). doi:10.1016/B978-012374178-3.10008-0.

15.          Vagima, Y. et al. MT1-MMP and RECK are involved in human CD34+ progenitor cell retention, egress, and mobilization. J. Clin. Invest. 119, 492–503 (2009).

16.          Wallach-Dayan, S. B., Rubinstein, A. M., Hand, C., Breuer, R. & Naor, D. DNA vaccination with CD44 variant isoform reduces mammary tumor local growth and lung metastasis. Mol. Cancer Ther. 7, 1615–1623 (2008).

17.          Naor, D., Wallach-Dayan, S. B., Zahalka, M. A. & Sionov, R. V. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin. Cancer Biol. 18, 260–267 (2008).

18.          Gonen, E., Nedvetzki, S., Naor, D. & Shpigel, N. Y. CD44 is highly expressed on milk neutrophils in bovine mastitis and plays a role in their adhesion to matrix and mammary epithelium. Vet. Res. 39, (2008).

19.          Weiss, L., Botero-Anug, A. M., Hand, C., Slavin, S. & Naor, D. CD44 gene vaccination for insulin-dependent diabetes mellitus in non-obese diabetic mice. Isr. Med. Assoc. J. 10, 20–25 (2008).

20.          Sebban, L. E. et al. The involvement of CD44 and its novel ligand galectin-8 in apoptotic regulation of autoimmune inflammation. J. Immunol. 179, 1225–1235 (2007).

21.          Garin, T. et al. CD44 variant DNA vaccination with virtual lymph node ameliorates experimental autoimmune encephalomyelitis through the induction of apoptosis. J. Neurol. Sci. 258, 17–26 (2007).

22.          Golan, I. et al. Expression of extra trinucleotide in CD44 variant of rheumatoid arthritis patients allows generation of disease-specific monoclonal antibody. J. Autoimmun. 28, 99–113 (2007).

23.          Naor, D. et al. CD44 involvement in autoimmune inflammations: The lesson to be learned from CD44-targeting by antibody or from knockout mice. Annals of the New York Academy of Sciences vol. 1110 233–247 (2007).

24.          DUKE‐COHAN, J. S. et al. Use of an autologous reaction in vitro to assess contributions of T and B lymphocytes to immune hyperreactivity of atopics. Clin. Exp. Allergy 19, 163–168 (1989).

25.          Nedvetzki, S. et al. Erratum: RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: A different interpretation of redundancy (Proceedings of the National Academy of Sciences of the United States of America (December 28, 2004) 101, 52 (18081-18086)). Proc. Natl. Acad. Sci. U. S. A. 102, 1263 (2005).

26.          Naor, D. et al. The mechanism of molecular redundancy in autoimmune inflammation in the context of CD44 deficiency. Annals of the New York Academy of Sciences vol. 1050 52–63 (2005).

27.          Nedvetzki, S. et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: A different interpretation of redundancy. Proc. Natl. Acad. Sci. U. S. A. 101, 18081–18086 (2004).

28.          Avigdor, A. et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood 103, 2981–2989 (2004).

29.          Naor, D. & Nedvetzki, S. CD4 in rheumatoid arthritis. Arthritis Res. Ther. 5, 105–115 (2003).

30.          Ursø, B. et al. IRS-4 mediated mitogenic signalling by insulin and growth hormone in LB cells, a murine T-cell lymphoma devoid of IGF-I receptors. Cell. Signal. 15, 385–394 (2003).

31.          Nedvetzki, S. et al. A mutation in a CD44 variant of inflammatory cells enhances the mitogenic interaction of FGF with its receptor. J. Clin. Invest. 111, 1211–1220 (2003).

32.          Guy, R., Yefenof, E., Naor, D., Dorogin, A. & Zilberman, Y. CD44 co-stimulates apoptosis in thymic lymphomas and T cell hybridomas. Cell. Immunol. 216, 82–92 (2002).

33.          Naor, D., Nedvetzki, S., Golan, I., Melnik, L. & Faitelson, Y. CD44 in cancer. Crit. Rev. Clin. Lab. Sci. 39, 527–579 (2002).

34.          Wallach-Dayan, S. B. et al. CD44-dependent lymphoma cell dissemination: A cell surface CD44 variant, rather than standard CD44, supports in vitro lymphoma cell rolling on hyaluronic acid substrate and its in vivo accumulation in the peripheral lymph nodes. J. Cell Sci. 114, 3463–3477 (2001).

35.          Batya Wallach, S., Friedmann, A. & Naor, D. The CD44 receptor of the mouse LB T-cell lymphoma: Analysis of the isoform repertoire and ligand binding properties by reverse-transcriptase polymerase chain reaction and antisense oligonucleotides. Cancer Detect. Prev. 24, 33–45 (2000).

36.          Weiss, L. et al. Induction of resistance to diabetes in non-obese diabetic mice by targeting CD44 with a specific monoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 97, 285–290 (2000).

37.          Rochman, M. et al. The CD44 receptor of lymphoma cells: Structure-function relationships and mechanism of activation. Cell Adhes. Commun. 7, 331–347 (2000).

38.          Nedvetzki, S. et al. CD44 involvement in experimental collagen-induced arthritis (CIA). J. Autoimmun. 13, 39–47 (1999).

39.          Sionov, R. V & Naor, D. Calcium- and calmodulin-dependent PMA-activation of the CD44 adhesion molecule. Cell Adhes. Commun. 6, 503–523 (1998).

40.          Naor, D. et al. Organ-specific requirements for cell adhesion molecules during lymphoma cell dissemination. Current Topics in Microbiology and Immunology vol. 231 143–166 (1997).

41.          Ish-Shalom, D. et al. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 40, S25–S31 (1997).

42.          Sionov, R. V & Naor, D. Hyaluronan-independent lodgment of CD44+ lymphoma cells in lymphoid organs. Int. J. Cancer 71, 462–469 (1997).

43.          Naor, D., Sionov, R. V & Ish-Shalom, D. CD44: Structure, function, and association with the malignant process. Advances in Cancer Research vol. 71 241–319 (1997).

44.          Gosslar, U. et al. Predominant role of α4-integrins for distinct steps of lymphoma metastasis. Proc. Natl. Acad. Sci. U. S. A. 93, 4821–4826 (1996).

45.          Rocha, M. et al. Dynamic expression changes in vivo of adhesion and costimulatory molecules determine load and pattern of lymphoma liver metastasis. Clin. Cancer Res. 2, 811–820 (1996).

46.          Urs⊘, B. et al. Mitogenic signalling by insulin in a T-cell lymphoma, the LB cell line, devoid of IGF-I receptors: Evidence for the lack of involvement of the RAS-MAP kinase pathway and for a possibly novel IRS-like molecule. Exp. Clin. Endocrinol. Diabetes 104, 52–53 (1996).

47.          ISH‐SHALOM, D. et al. Mitogenic Potential of Insulin on Lymphoma Cells Lacking IGF‐1 Receptor. Annals of the New York Academy of Sciences vol. 766 409–414 (1995).

48.          Zahalka, M. A., Okon, E., Gosslar, U., Holzmann, B. & Naor, D. Lymph node (but not spleen) invasion by murine lymphoma is both CD44- and hyaluronate-dependent. J. Immunol. 154, 5345–5355 (1995).

49.          Stock, R. & Naor, D. Induction of an autoimmune response against syngeneic lymphoma cells by immunogenic 64-kDa protein isolated from normal blast cells of BALB/c mice. Cancer Immunol. Immunother. 40, 48–56 (1995).

50.          Zahalka, M. A. & Naor, D. β2-lntegrin dependent aggregate formation between LB T cell lymphoma and spleen cells: Assessment of correlation with spleen invasiveness. Int. Immunol. 6, 917–924 (1994).

51.          Zahalka, M. A., Okon, E. & Naor, D. Blocking Lymphoma Invasiveness with a Monoclonal Antibody Directed against the β-Chain of the Leukocyte Adhesion Molecule (CD18). J. Immunol. 150, 4466–4477 (1993).

52.          Sharon, R. et al. Insulin dependence of murine T‐cell lymphoma. II. Insulin‐deficient diabetic mice and mice fed low‐energy diet develop resistance to lymphoma growth. Int. J. Cancer 53, 843–849 (1993).

53.          Naor, D. Bifunctional T cell clones challenge the traditional compartmentalization concept of the immune system. Arch. Immunol. Ther. Exp. (Warsz). 40, 67–70 (1992).

54.          Sharon, R. & Naor, D. Experimental model of autoimmune hemolytic anemia induced in mice with levodopa by intraperitoneal injection or oral feeding. Int. J. Immunopharmacol. 14, 1241–1247 (1992).

55.          Pillemer, G., Lugasi‐Evgi, H., Scharovsky, G. & Naor, D. Insulin dependence of murine lymphoid T‐cell leukemia. Int. J. Cancer 50, 80–85 (1992).

56.          Naor, D. A different outlook at the phenotype-function relationships of T cell subpopulations: Fundamental and clinical implications. Clin. Immunol. Immunopathol. 62, 127–132 (1992).

57.          NAOR, D., ESSERY, G., TARCIC, N., KAHAN, M. & FELDMANN, M. Regulatory Interactions among Autologous T Cell Clones Human Bifunctional T Cell Clones Regulate the Activity of an Autologous T Cell Clone. Annals of the New York Academy of Sciences vol. 636 135–146 (1991).

58.          Zahalka, M. A. & Naor, D. Inflammatory response induced with an isolated syngeneic activation antigen shared by normal lymphoblasts and YAC lymphoma cells. Clin. Immunol. Immunopathol. 59, 72–88 (1991).

59.          Naor, D., Essery, G., Tarcic, N., Kahan, M. & Feldmann, M. Interactions between autologous T cell clones. Cell. Immunol. 128, 490–502 (1990).

60.          Naor, D. et al. Specific Interactions between a Human CD4+ Clone and Autologous CD4+ Bifunctional Immunoregulatory Clones. Immunol. Rev. 116, 63–83 (1990).

61.          Lugasi, H. et al. Murine spontaneous T‐cell leukemia constitutively expressing IL‐2 receptor—a model for human T‐cell malignancies expressing IL‐2 receptor. Int. J. Cancer 45, 163–167 (1990).

62.          Duke-Cohan, J. S., Rubinow, A., Hirt, R. & Naor, D. The reaction against autologous lymphoblasts as an indicator of lymphocyte hyperreactivity in rheumatoid arthritis. Clin. Immunol. Immunopathol. 54, 298–308 (1990).

63.          Alvarez, E. et al. The inter-relationships between spontaneous murine T cell leukaemia LB and the immune system: LB is a nonimmunogenic tumor in its syngeneic host. J. Exp. Clin. Cancer Res. 8, 181–192 (1989).

64.          Naor, D., Essery, G., Kahan, M. & Feldmann, M. T-cell clone anti-clone interactions. Effects on suppressor and helper activities. J. Autoimmun. 2, 3–14 (1989).

65.          Naor, D. et al. Autoreactivity against class I or class II antigens - Immunological downregulation mechanism? Bull. Inst. Pasteur 87, 3–17 (1989).

66.          Sharon, R. & Naor, D. Experimental model of autoimmune hemolytic anemia induced in mice with Levodopa. Clin. Immunol. Immunopathol. 52, 160–172 (1989).

67.          Tarcic, N., David, C. S. & Naor, D. Auto-delayed-type hypersensitivity induced in immunodeficient mice with modified self-antigens. V. Cellular autoreactivity directed against self-H-2D(d) subregion mediates the inflammatory responses. Immunology 67, 184–190 (1989).

68.          Sharon, R., Giloh, H. & Naor, D. Experimental autoimmune anemia induced with haptenated syngeneic mouse red blood cells and low dose X-irradiation. Clin. Immunol. Immunopathol. 47, 310–322 (1988).

69.          KLEIN, I. & NAOR, D. Self‐Reactive Delayed Type Hypersensitivity Induced in Mice by Syngeneic Lymphoblasts: III. Immunological Characterization of the Small and Large Antigens of the Blast Cells. Scand. J. Immunol. 27, 385–392 (1988).

70.          Klein, I. & Naor, D. Autoinflammatory response to self-antigens of lymphoblasts. Isr. J. Med. Sci. 24, 373–374 (1988).

71.          KLEIN, I., KLEIN, B. Y. & NAOR, D. Self‐Reactive Delayed Type Hypersensitivity Induced in Mice by Syngeneic Lymphoblasts: II. Isolation of Two Distinct Lymphoblast Antigens, One of Which Reacts (or Cross‐Reacts) with Anti‐H‐2Dd Monoclonal Antibody. Scand. J. Immunol. 27, 209–222 (1988).

72.          Naor, D. Suppressor cells and human malignancy. Clin. Immunol. Newsl. 8, 65–69 (1987).

73.          Duke-Cohan, J. S., Hirt, R., Dahan, A. & Naor, D. On the immune reaction to autologous human lymphoblasts: Evidence for the stimulation by activating factors rather than induction by autoantigens. Clin. Immunol. Immunopathol. 43, 229–242 (1987).

74.          Naor, D. & Duke-Cohan, J. S. Suppressor cells and malignancy. I. Suppressor macrophages and suppressor T cells in experimental animals. Adv. Immun. Cancer Ther. 2, 1–129 (1986).

75.          Kelley, V. E., Naor, D., Tarcic, N., Gaulton, G. N. & Strom, T. B. Anti-interleukin 2 receptor antibody suppresses delayed-type hypersensitivity to foreign and syngeneic antigens. J. Immunol. 137, 2122–2124 (1986).

76.          Tarcic, N. & Naor, D. The genetic control of syngeneic delayed type hypersensitivity (syn-DTH). Immunogenetics 24, 131–134 (1986).

77.          Hutchings, P., Naor, D. & Cooke, A. Effects of low doses of cyclophosphamide and low doses of irradiation on the regulation of induced erythrocyte autoantibodies in mice. Immunology 54, 97–104 (1985).

78.          Naor, D., Tarcic, N. & Baler, R. Control of in vivo immunological autoreactivities with suppressive T cell factor derived from a hybridoma cell line. Transplant. Proc. 17, 2617–2621 (1985).

79.          Langer, A., Rosenmann, E. & Naor, D. The effect of cyclosporin on murine autoreactive delayed type hypersensitivity induced with syngeneic lymphoblasts. Immunopharmacology 10, 147–155 (1985).

80.          Naor, D. & Langer, A. Analysis of the cyclosporine mechanism in an immunological autoreactive model of delayed-type hypersensitivity. Transplant. Proc. 17, 2706–2708 (1985).

81.          Duke-Cohan, J. S., Weinberg, H., Sharon, R. & Naor, D. Immunological function in osteoporosis. Clin. Immunol. Immunopathol. 35, 125–129 (1985).

82.          Klein, I. & Naor, D. Self Reactive Delayed Type Hypersensitivity (DTH) Induced in Mice by Syngeneic Lymphoblasts. Immunobiology 169, 45–59 (1985).

83.          Klein, B. Y., Frenkel, S. & Naor, D. Isolated soluble fractions from the murine B16 melanoma induce primary in vitro syngeneic antitumor responses. Cancer Immunol. Immunother. 18, 195–202 (1984).

84.          Sharon, R. & Naor, D. The isolation of immunogenic molecular entities from immunogenic and nonimmunogenic tumor homogenates by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Cancer Immunol. Immunother. 18, 203–208 (1984).

85.          TARCIC, N., BALER, R. & NAOR, D. Auto‐Delayed‐Type Hypersensitivity Induced in Immunodeficient Mice withModified Self‐Antigens: III. Suppressive T‐Cell Factor Controls the Autoreactivity against Self‐Antigens. Scand. J. Immunol. 20, 389–401 (1984).

86.          TARCIC, N., KLEIN, B. Y. & NAOR, D. Auto‐Delayed‐Type Hypersensitivity Induced in Immunodeficient Mice with Modified Self‐Antigens: IV. Characterization of the Suppressive T‐Cell Factor that Controls the Autoreactivity against Self‐Antigens. Scand. J. Immunol. 20, 403–411 (1984).

87.          Adler, A., Stein, J. A., Kedar, E., Naor, D. & Weiss, D. W. Intralesional injection of interleukin-2 — Expanded autologous lymphocytes in melanoma and breast cancer patients: A pilot study. J. Biol. Response Mod. 3, 491–500 (1984).

88.          TARCIC, N., SHARON, R., ROSENMANN, E. & NAOR, D. Auto‐Delayed‐Type Hypersensitivity Induced in Immunodeficient Mice with Syngeneic Modified Self‐Antigens: II. Suppressor T Cells Control the Autoimmune Response. Scand. J. Immunol. 19, 111–121 (1984).

89.          Klein, B. Y., Frenkel, S. & Naor, D. Isolation of murine melanoma antigens crossreactive with human melanoma antigens, detected by cell mediated cytotoxicity. Fed. Proc. 43, (1984).

90.          Naor, D. Coexistence of immunogenic and suppressogenic epitopes in tumor cells and various types of macromolecules. Cancer Immunol. Immunother. 16, 1–10 (1983).

91.          Ahituv, A., Naor, D., Sharon, R., Tarcic, N. & Klein, B. Y. Immunogenicity of subcellular fractions and molecular species of MuLV-induced tumors - III. Stimulation of syngeneic antitumor responses by subcellular fractions and molecular species of moloney virus-induced tumors in CBA and a mice. Cancer Immunol. Immunother. 14, 16–26 (1982).

92.          Klein, B. Y., Sharon, R., Tarcic, N. & Naor, D. Induction of Antitumor Reactive Cells or Suppressor Cells by Different Molecular Species Isolated from the Same Nonimmunogenic Tumor. Immunobiology 163, 7–21 (1982).

93.          Tarcic, N. & Naor, D. Delayed‐type hypersensitivity induced in immunodeficient mice with syngeneic modified self antigens: a suggestive model of autoimmune response. Eur. J. Immunol. 12, 961–966 (1982).

94.          Naor, D. & Tarcic, N. CONTROL OF AUTOIMMUNE RESPONSES INDUCED WITH MODIFIED SELF ANTIGENS. Annals of the New York Academy of Sciences vol. 392 178–190 (1982).

95.          Klein, B. Y. et al. Isolation of immunogenic and suppressogenic determinants of the nonimmunogenic YAC tumor and the change in its immunogenic repertoire after in vitro cultivation. Transplant. Proc. 13, 790–797 (1981).

96.          Kobrin, B. J., Naor, D. & Klein, B. Y. Immunogenicity of subcellular fractions and molecular species of MuLV-induced tumors. II. Stimulation of syngeneic anti-tumor cell-mediated immune responses by subcellular fractions and molecular species of the Rauscher-virus-induced RBL5 tumor. J. Immunol. 126, 1874–1882 (1981).

97.          Devens, B., Deutsch, O., Avraham, Y. & Naor, D. Immune Response to Weakly Immunogenic Virally Induced Tumors. IX. Mice Injected with the in vitro Variant of YAC Tumor (YAC-1) Resist Lethal Doses of the Tumorgenic YAC Cells. Immunobiology 159, 432–443 (1981).

98.          Naor, D. Unresponsiveness to Modified Self Antigens ‐ A Censorship Mechanism Controlling Autoimmunity? Immunol. Rev. 50, 187–226 (1980).

99.          Klein, B. Y., Frenkel, S., Ahituv, A. & Naor, D. Immunogenicity of subcellular fractions and molecular species of MuLV-induced tumors. I. screening of immunogenic components by isopycnic ultracentrifugation and polyacrylamide electrophoresis of a tumor homogenate. J. Immunol. Methods 38, 325–341 (1980).

100.        Leshem, B. & Naor, D. Studies on the immune response to fixed antigens. IV. Recall of immunologic memory with fixed antigens. Isr. J. Med. Sci. 16, 25–32 (1980).

101.        Deutsch, O., Devens, B. & Naor, D. Immune responses to weakly immunogenic murine-leukemia-virus-induced tumors. VII. Kinetic studies on various parameters of effects induced with suppressor cells. Isr. J. Med. Sci. 16, 530–537 (1980).

102.        Deutsch, O., Devens, B. & Naor, D. Immune responses to weakly immunogenic murine-leukemia-virus-induced tumors. VIII. Characterization of suppressor cells. Isr. J. Med. Sci. 16, 538–544 (1980).

103.        Devens, B. & Naor, D. Immune responses to weakly immunogenic virally induced tumors. VI. Comparison of the immune response of the hybrid to the immune responses of the parents reveals ‘hybrid responsiveness’ effect. J. Immunol. 125, 988–994 (1980).

104.        Devens, B., Naor, D. & Kedar, E. Immune response to weakly immunogenic virally induced tumors iv dissociated recognition of H-2 and tumor associated antigens: IV dissociated recognition of h 2 and tumor associated antig4ens. Transplantation 28, 389–395 (1979).

105.        Devens, B., Schochot, L. & Naor, D. Immune responses to weakly immunogenic virally induced tumors. V. Short in vitro cultivation of YAC changes its antigenic properties. Cell. Immunol. 44, 442–453 (1979).

106.        Naor, D. Suppressor cells: Permitters and promoters of malignancy? Advances in Cancer Research vol. 29 45–125 (1979).

107.        Devens, B. & Naor, D. Immune responses to weakly immunogenic virally induced tumors. III. Genetically unrestricted cytolysis of allogeneic tumor target cells. J. Immunol. 122, 1397–1401 (1979).

108.        Ashman, R. F. & Naor, D. Membrane defects of the tolerant B cell. I. Failure of antigen-induced capping. Cell. Immunol. 44, 314–328 (1979).

109.        Leshem, B. & Naor, D. Studies on the immune response to fixed antigens. III. Induction of helper function for antibody-dependent cellular cytotoxicity responses. J. Immunol. 121, 401–408 (1978).

110.        Devens, B., Galili, N., Deutsch, O., Naor, D. & Klein, E. Immune responses to weakly immunogenic virally induced tumors II. Suppressive effects of the in vivo carried tumor YAC. Eur. J. Immunol. 8, 573–578 (1978).

111.        Leshem, B. & Naor, D. Cellular assay for measuring anti-erythrocyte antibody responses. J. Immunol. Methods 20, 263–275 (1978).

112.        Galili, N., Devens, B., Naor, D., Becker, S. & Klein, E. Immune responses to weakly immunogenic virally induced tumors I. Overcoming low responsiveness by priming mice with a syngeneic in vitro tumor line or allogeneic cross‐reactive tumor. Eur. J. Immunol. 8, 17–22 (1978).

113.        Naor, D. & O’Toole, C. Cryopreservation of immunological memory and other lymphoid cell functions. J. Immunol. Methods 16, 361–370 (1977).

114.        Naor, D. & Kahan, M. Studies on the immune response to fixed antigens. II. Optimal conditions for inducing and eliciting helper function by fixed antigens and the mechanism responsible for this effect. Isr. J. Med. Sci. 13, 561–576 (1977).

115.        Naor, D. & Galili, N. Immune response to chemically modified antigens. Prog. Allergy Vol. 22, 107–146 (1977).

116.        Kedar, E. et al. Immunogenicity of tumor cells modified by trinitrobenzene suflonic acid (TNBS). Prog. Clin. Biol. Res. 9, 109–121 (1976).

117.        Kahan, M., Berman Goldman, R., Salton, R. & Naor, D. Studies on the immune response to fixed antigens. Preferential induction of helper function with heavily trinitrophenylated sheep erythrocytes, and glutaraldehyde treated sheep erythrocytes. J. Immunol. 117, 16–22 (1976).

118.        Naor, D., Bonavida, B. & Walford, R. L. Autoimmunity and aging: the age related response of mice of a long lived strain to trinitrophenylated syngeneic mouse red blood cells. J. Immunol. 117, 2204–2208 (1976).

119.        Galili, N., Naor, D., Åsjö, B. & Klein, G. Induction of immune responsiveness in a genetically low‐responsive tumor‐host combination by chemical modification of the immunogen. Eur. J. Immunol. 6, 473–476 (1976).

120.        Naor, D. et al. Immune response of New Zealand mice to trinitrophenylated syngeneic mouse red cells. Eur. J. Immunol. 6, 783–789 (1976).

121.        Naor, D. et al. Induction of hapten recognizing helper function by heavily trinitrophenylated sheep erythrocytes. Adv. Exp. Med. Biol. 66, 253–260 (1976).

122.        Naor, D., Falkenberg, F. & Saltoun, R. Proceedings: Mouse immune response to trinitrophenylated red cells. Isr. J. Med. Sci. 11, 1377–1378 (1975).

123.        Naor, D., Saltoun, R. & Falkenberg, F. Lack of requirement for thymocytes for efficient antibody formation to trinitrophenylated mouse red cells in mice: Role for thymocytes in suppression of the immune response. Eur. J. Immunol. 5, 220–223 (1975).

124.        Zolla, S., Naor, D. & Tanapatchaiyapong, P. Cellular basis of immunodepression in mice with plasmacytomas. J. Immunol. 112, 2068–2076 (1974).

125.        Zolla, S. & Naor, D. Restoration of immune competence in tolerant mice by parabiosis to normal mice. J. Exp. Med. 140, 1421–1426 (1974).

126.        Sulitzeanu, D., Morecki, S. & Naor, D. Specific interactions of antigen with cells studied by means of rosette formation. Isr. J. Med. Sci. 10, 1397–1404 (1974).

127.        Naor, D., Morecki, S. & Mitchell, G. F. Differential induction of anti‐trinitrophenyl plaque‐forming cell responses to lightly and heavily conjugated trinitrophenylated heterologous and autologous erythrocytes in mice. Eur. J. Immunol. 4, 311–314 (1974).

128.        Naor, D., Morecki, S. & Kedar, E. Differential induction and suppression of direct and indirect PFC responses to TNP conjugated to heterologous erythrocytes. Adv. Exp. Med. Biol. 29, 225–232 (1973).

129.        Naor, D. & Mishell, R. In vitro immunity to TNP and penicillin: specific inhibition with hapten-conjugated isologous red cells. J. Immunol. 108, 246–252 (1972).

130.        Naor, D., Henry, C. & Fudenberg, H. H. An in vitro immune response to penicillin. J. Immunol. 107, 302–305 (1971).

131.        Wofsy, L., Truffa‐Bachi, P. & Naor, D. CHEMICAL APPROACHES TO THE CELL RECEPTOR PROBLEM. Annals of the New York Academy of Sciences vol. 190 432–442 (1971).

132.        Naor, D., Mishell, R. I. & Wofsy, L. Specific inhibition of an anti-hapten immune response by chemical modifications of cells. J. Immunol. 105, 1322–1326 (1970).

133.        Naor, D. & Sulitzeanu, D. Affinity of radioiodinated bovine serum albumin for lymphoid cells. 3. Further experiments with cells of normal animals. Isr. J. Med. Sci. 6, 519–522 (1970).

134.        Naor, D. The structure of immunoglobulins. Harefuah 77, 528 (1969).

135.        Naor, D. & Sulitzeanu, D. Affinity of radioiodinated bovine serum albumin for lymphoid cells. Binding of I-125-BSA to lymphoid cells of immune mice. Isr. J. Med. Sci. 5, 217–229 (1969).

136.        Naor, D., Bentwich, Z. & Cividalli, G. Inability of peripheral lymphoid cells of agammaglobulinaemic patients to bind radioiodinated albumins. Aust. J. Exp. Biol. Med. Sci. 47, 759–761 (1969).

137.        Naor, D. & Sulitzeanu, D. Binding of 125I-BSA to lymphoid cells of tolerant mice. Int. Arch. Allergy Appl. Immunol. 36, 112–113 (1969).

138.        Sulitzeanu, D. & Naor, D. The affinity of radioiodinated BSA for lymphoid cells. II. Binding of 125I-BSA to lymphoid cells of normal mice. Int. Arch. Allergy Appl. Immunol. 35, 564–578 (1969).

139.        Naor, D. & Sulitzeanu, D. Binding of radioiodinated bovine serum albumin to lymphoid cells of specifically primed or immunized mice in vitro. Life Sci. 7, 377–382 (1968).

140.        Naor, D. & Sulitzneau, D. Binding of radioiodinated bovine serum albumin to mouse spleen cells. Nature 214, 687–688 (1967).

141.        Gesundheit, B. et al. Immunological and autoimmune considerations of Autism Spectrum Disorders. J. Autoimmun. 44, 1–7 (2013).